ANI Pharmaceuticals CFO gets stock grant, tax withholding

ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported two equity transactions in company common stock.

Accepted by SEC EDGAR 03/02/2026 - 05:57 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported two equity transactions in company common stock. On February 26, 2026, he received a grant of 22,233 restricted shares at $77.15 per share, which will vest in four equal annual installments starting on the first anniversary of that date. On February 28, 2026, 2,773 shares at $73.90 per share were disposed of for tax withholding in connection with the vesting of 6,079 previously granted restricted shares. After these transactions, he directly owned 189,543 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider CAREY STEPHEN P.

Role SVP & CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,773	$73.90	$205K
Grant/Award	Common Stock	22,233	$77.15	$1.72M

Holdings After Transaction: Common Stock — 189,543 shares (Direct)

Holdings Before and After: Common Stock, 170,083 to 189,543 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.
2. F2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,079 shares of restricted stock, the grant of which was previously reported.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ANI Pharmaceuticals (ANIP) report for Stephen P. Carey?

ANI Pharmaceuticals reported that SVP & CFO Stephen P. Carey received a grant of 22,233 restricted common shares and had 2,773 shares withheld for taxes related to vesting. Both positions are reported as directly owned common stock.

Was the ANI Pharmaceuticals (ANIP) insider transaction a stock sale on the market?

The disposition of 2,773 ANI Pharmaceuticals shares was for tax withholding, not an open-market sale. The filing describes it as shares withheld for tax purposes in connection with the vesting of 6,079 previously granted restricted shares.

How many restricted shares did the ANI Pharmaceuticals (ANIP) CFO receive and how do they vest?

The ANI Pharmaceuticals SVP & CFO received 22,233 restricted common shares. According to the filing, this restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.

What is Stephen P. Carey’s reported ANI Pharmaceuticals (ANIP) share ownership after these transactions?

Following the reported grant and tax-withholding disposition, Stephen P. Carey is shown as directly owning 189,543 shares of ANI Pharmaceuticals common stock. This figure reflects his holdings after both Form 4 transactions were recorded.

What do the Form 4 transaction codes A and F mean for ANI Pharmaceuticals (ANIP)?

For this ANI Pharmaceuticals filing, code A indicates a grant or award acquisition of 22,233 restricted shares. Code F reflects 2,773 shares disposed of to satisfy tax obligations tied to vesting of previously granted restricted stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAREY STEPHEN P.

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		22,233	A	$77.15	192,316	D
Common Stock	02/28/2026		F(2)		2,773	D	$73.9	189,543	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,079 shares of restricted stock, the grant of which was previously reported.

Remarks:

	/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.